{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sourbron J"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["77-89"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9977757"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["Objective
Antiseizure medications (ASMs) remain the mainstay of epilepsy treatment. These ASMs have mainly been tested in trials in adults with epilepsy, which subsequently led to market authorization (MA). For treatment of - especially young - children with epilepsy, several ASMs do not have a MA and guidelines are lacking, subsequently leading to \"off-label\" use of ASMs. Even though \"off-label\" ASM prescriptions for children could lead to more adverse events, it can be clinically appropriate and rational if the benefits outweigh the risks. This could be the case if \"on-label\" ASM, in mono- or polytherapy, fails to achieve adequate seizure control.Methods
The Medical Therapies Task Force of the International League Against Epilepsy (ILAE) Commission for Pediatrics performe"],"journal":["Epilepsia open"],"pubmed_title":["Medical treatment in infants and young children with epilepsy: Off-label use of antiseizure medications. Survey Report of ILAE Task Force Medical Therapies in Children."],"pmcid":["PMC9977757"],"funding_grant_id":["NF-SI-0515-10073"],"pubmed_authors":["Arzimanoglou A","Sourbron J","Wilmshurst JM","Yozawitz E","Auvin S","Cross JH","Pressler R","Lagae L","Sugai K","Hartmann H","Riney K"],"additional_accession":[]},"is_claimable":false,"name":"Medical treatment in infants and young children with epilepsy: Off-label use of antiseizure medications. Survey Report of ILAE Task Force Medical Therapies in Children.","description":"Objective
Antiseizure medications (ASMs) remain the mainstay of epilepsy treatment. These ASMs have mainly been tested in trials in adults with epilepsy, which subsequently led to market authorization (MA). For treatment of - especially young - children with epilepsy, several ASMs do not have a MA and guidelines are lacking, subsequently leading to \"off-label\" use of ASMs. Even though \"off-label\" ASM prescriptions for children could lead to more adverse events, it can be clinically appropriate and rational if the benefits outweigh the risks. This could be the case if \"on-label\" ASM, in mono- or polytherapy, fails to achieve adequate seizure control.Methods
The Medical Therapies Task Force of the International League Against Epilepsy (ILAE) Commission for Pediatrics performe","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-03-18T13:46:37.412Z","creation":"2025-04-19T09:19:15.633Z"},"accession":"S-EPMC9977757","cross_references":{"pubmed":["36281833"],"doi":["10.1002/epi4.12666"]}}